Commercializing Living Therapies with CCRM
Commercializing Living Therapies with CCRM
Latest Episodes
Convergence, collaboration and commercialization in cell and gene therapies
Featuring:Molly Shoichet, PhD, O.C., O. Ont., FRS, University Professor and Pamela & Paul Austin Chair in Precision & Regenerative Medicine, University of TorontoAudrey Greenberg, MBA, CEO & Founder, AG Capital Advisor...
Investing in the future of medicine: Trends, hurdles and opportunities in the CGT sector
Reni Benjamin, Managing Director, Healthcare Equity Research at CitizensBrock Reeve, CEO and Co-founder, Eos BioInnovation***In this episode of Commercializing Living Therapies with CCRM, host Krista Lamb speaks wi...
Navigating commercialization: Regional hubs, global solutions
Featuring:Silvio Tiziani, CEO, CCRM AustraliaSarah Callens, CTO, CCRM Nordic***In this episode of Commercializing Living Therapies with CCRM, Silvio Tiziani, CEO, CCRM Australia, and Sarah Callens, CTO, CCRM...
Enabling patient access to cell and gene therapies
Featuring:Durhane Wong-Rieger, PhD, President and CEO, Canadian Organization for Rare DisordersJacqueline Barry, PhD, Chief Clinical Officer, Cell and Gene Therapy Catapult***In this episode, we dive into the critica...
Unapproved stem cell therapies: Risks, realities and responsibilities
Featuring:Paul Knoepfler, PhD, Professor of Cell Biology and Human Anatomy, UC Davis School of MedicineAmy Zarzeczny, PhD LLM, Associate Professor, Johnson Shoyama Graduate School of Public Policy, University of Regina***
